Breaking News - The Fly

Open Search

ATXI

Avenue Therapeutics

$

()

Avenue Therapeutics granted extension for Nasdaq compliance

ATXI

3/15/2024 - 08:23am

Avenue Therapeutics to presents BAER-101 preclinical data at ASENT meeting

ATXI

3/11/2024 - 08:26am

Avenue Therapeutics announces publication of preclinical data of BAER-101

ATXI

2/22/2024 - 08:43am

Avenue Therapeutics files to sell 33.08M shares of common stock for holders

ATXI

1/24/2024 - 16:18pm

Avenue Therapeutics enters warrant exercise transactions for $5M in procceeds

ATXI

1/5/2024 - 09:18am

Avenue Therapeutics reaches final agreement with FDA for Phase 3 safety study

ATXI

1/4/2024 - 08:33am

Avenue announces completion of enrollment in Phase 1b/2a trial of AJ201

ATXI

1/2/2024 - 08:32am

Avenue Therapeutics initiated yesterday with a Buy at Maxim

ATXI

12/12/2023 - 07:59am

Avenue Therapeutics initiated with bullish view at Maxim

ATXI

12/11/2023 - 08:06am

Avenue Therapeutics to present preclinical in vivo data on BAER-101

ATXI

12/1/2023 - 08:33am

Avenue Therapeutics reports Q3 EPS 6c vs (45c) last year

ATXI

11/13/2023 - 16:42pm

Avenue Therapeutics prices 16.6M units at 30.06c in public offering

ATXI

10/31/2023 - 09:21am

Avenue Therapeutics files to sell units, no amount given

ATXI

9/18/2023 - 17:21pm

Avenue announces BAER-101 'significantly suppressed' seizures in model

ATXI

8/1/2023 - 08:37am

Avenue Therapeutics announces first patient dosed in Phase 1b/2a trial of AJ201

ATXI

7/27/2023 - 08:37am